Kissei Pharmaceutical Co., Ltd. (TYO:4547)

Japan flag Japan · Delayed Price · Currency is JPY
4,645.00
+45.00 (0.98%)
At close: Mar 5, 2026
Market Cap192.54B +20.9%
Revenue (ttm)95.29B +14.3%
Net Income14.14B +21.2%
EPS337.35 +27.2%
Shares Out41.45M
PE Ratio13.77
Forward PE15.44
Dividend120.00 (2.61%)
Ex-Dividend DateMar 30, 2026
Volume114,600
Average Volume102,010
Open4,670.00
Previous Close4,600.00
Day's Range4,640.00 - 4,730.00
52-Week Range3,480.00 - 5,040.00
Beta-0.24
RSI46.78
Earnings DateMay 7, 2026

About Kissei Pharmaceutical

Kissei Pharmaceutical Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in Japan. The company offers Calogra tablets, for the treatment of ulcerative colitis; Tabneos capsules for the treatment of microscopic polyangiitis and granulomatous polyangiitis; Minirin Melt OD tablets; Corsuba Intravenous Dialysis Syringe for the treatment of chronic idiopathic thrombocytopenic purpura; Beova tablets for the treatment of overactive bladder treatment; and Darbepoetin Alfa BS injection JCR for the treatment of rena... [Read more]

Sector Healthcare
Founded 1946
Employees 1,778
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4547
Full Company Profile

Financial Performance

In fiscal year 2025, Kissei Pharmaceutical's revenue was 88.33 billion, an increase of 16.87% compared to the previous year's 75.58 billion. Earnings were 11.96 billion, an increase of 7.18%.

Financial Statements